TABLE I.

Baseline clinical characteristics of patients

	Age (y), sex		GI tissue eosinophilia*
No.		GI symptoms (active, historic)	E	G	D	C	Comorbid atopic disease	Therapies (active, historic)
6†	48 F	Diarrhea (3× daily) Abdominal pain Dysphagia	−	+	−	+	Asthma	P, HU, IFN
7	35 M	Bloating Constipation Abdominal pain (daily, with monthly exacerbation) Diarrhea, weight loss, dysphagia, odynophagia, nausea, early satiety	+	+	+	−	Asthma, FA (crab, almond; avoids shellfish and nuts), allergic rhinitis	P, topical budesonide, FV, hydroxychloroquine, sirolimus‡
11	53 M	Abdominal pain Diarrhea (3× /wk) dysphagia early satiety, weight loss	+	+	+	−	Asthma	P, topical budesonide
13	37 F	Diarrhea (5–7× daily) Nausea (daily) Pill dysphagia Abdominal pain	−	+	+	+		P, Elemental diet, enterocort, cromolyn
14	23 F	Abdominal pain/cramping (daily) Diarrhea (multiple times a day) Dysphagia	+	+	+	−	Asthma, FA (wheat, suspected dairy)	Elemental diet, dietary therapy, topical budesonide, cromolyn, FV, sirolimus‡
15†	35 F	Diarrhea Abdominal pain Intermittent dysphagia	−	−	−	+		P, FV, IFN
16	33 F	Nausea (constant, weekly worsening) Dysphagia (daily)	+	+	−	−	Asthma, AR, FA (shrimp)	P, IFN, FV, cromolyn, topical budesonide, sirolimus,‡ dietary therapy

Budesonide, Budesonide slurry; C, colon; D, duodenum; E, esophageal; F, female; FA, food allergy; FV, swallowed flovent (fluticasone); G, gastric; HU, hydroxyurea; P, prednisone.

Historic symptoms and therapies as well as active GI symptoms and therapies at trial enrollment (bolded) are listed.

^*Tissue eosinophilia meeting criteria as described in methods.

^†Subjects with lymphoid HES whose disease also included GI manifestations. Remaining subjects had HES single-organ overlap (EGID).

^‡Sirolimus given under phase I clinical trial.